GO
Loading...

Pfizer Inc

More

  • Trexima Study Update: No Hamsters Harmed Friday, 3 Aug 2007 | 2:44 PM ET
    Chinese Hamsters

    I have a clarification to make regarding my previous blog entry about the Chinese Hamster problem facing GlaxoSmithKline and Pozen. Thanks to blog-reader Brian Orelli with www.babybiotechs.com who caught the error and pointed it out in an email: "Chinese Hamster Ovary (CHO) cells are grown in tissue culture and the mega dose of the drug was given to the CHO cells growing in media in a tissue culture dish/flask in an incubator...

  • Deciphering the Dow Thursday, 2 Aug 2007 | 7:22 PM ET

    Despite predictions that the Dow would be down big, the index posted a triple-digit gain for the second day in a row. So what's the deal?Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • Healing Healthcare: Wall Street Winners & Losers Saturday, 28 Jul 2007 | 1:18 PM ET

    As the push for universal health care in the U.S. heats up on Capitol Hill, market experts say generic drug stocks and pharmaceutical distributors should perform well, while the hit to big pharma may not be as bad as some anticipate.

  • It's Time for the Lightning Round! Friday, 27 Jul 2007 | 10:09 AM ET

    Peabody Energy, IHOP, Intel and more...Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • I think I just killed a tree. This morning I printed out the GlaxoSmithKline and FDA documents that were posted on the agency's Web site ahead of the advisory committee meeting on Avandia safety next Monday. About 700 pages! Nearly as many pages as the new "Harry Potter" book, but not nearly as entertaining.

  • UCB Profit Fell 39% in First Half Thursday, 26 Jul 2007 | 7:15 AM ET

    Belgian drug maker UCB Group said Thursday first-half net profit fell 39% as it absorbed the cost of taking over Germany's Schwarz Pharm.

  • Glaxo Doubles Buyback to $25 Billion as Earnings Flatten Wednesday, 25 Jul 2007 | 10:57 AM ET

    GlaxoSmithKline more than doubled its share buyback programme to 12 billion pounds ($25billion) on Wednesday, boosting its shares even as sliding sales of diabetes drug Avandia held back second-quarter profit.

  • With little or no fanfare Pfizer launched a new ad campaign for its erectile dysfunction drug Viagra on NBC Nightly News last night. Pfizer has gotten into a bit of trouble before for its relatively racy Viagra spots like the "Horny Devil" campaign featuring the guy with two horns growing out of his head. This time it's got a bunch of 40-something guys sitting around a dusty barn singing "Viva Viagra" to the tune of Elvis' "Viva Las Vegas".

  • Lilly Beats Second-Quarter Forecasts, Raises 2007 View Tuesday, 24 Jul 2007 | 8:01 AM ET

    Eli Lilly Tuesday posted better-than-expected second-quarter earnings helped by surging sales of its prescription drugs, including depression treatment Cymbalta, and the company raised its 2007 profit forecast.

  • A new study shows lowering cholesterol could increase the risk of cancer.  The Journal of the American College of Cardiology reports that researchers observed as much as triple the incidence of cancer among patients who lowered their bad or LDL cholesterol using the popular drugs known as statins.

  • Schering-Plough on Monday said second-quarter earnings more than doubled, driven by growing demand for its Zetia and Vytorin cholesterol drugs and its treatments for arthritis and allergies.

  • The Week On Wall Street: Hello, Goodbye 14,000 Friday, 20 Jul 2007 | 4:12 PM ET

    Investors picked up where they left off a week ago, as stock prices hurtled to new highs with the Dow Industrials setting another milestone, but a Friday selloff kind of spoiled the mood.

  • Pfizer Proposes Pay-for-Performance Thursday, 19 Jul 2007 | 3:41 PM ET

    Pfizer's "pay-for-performance" policy -- which essentially amounts to a money-back guarantee to pharmaceutical users and healthcare payers -- will be a boon for pharmaceutical companies, Catherine Arnold, director at Credit Suisse, said on "Power Lunch."

  • Pfizer's Kindler: Having to Explain The Lipitor Slip Thursday, 19 Jul 2007 | 2:25 PM ET
    Jeff Kindler

    Pfizer Chairman and CEO Jeff Kindler had some explaining to do on the company's earnings conference call this afternoon. He started by telling analysts, investors and reporters who were listening in (everyone's in a listen-only mode, only the analysts are allowed to ask questions), "Let me be direct. It was a tough quarter."

  • The buzz on the street on this morning is "earnings", says Scott Fullman, director of investment strategy for IA Englander & Co.

  • Stocks Make Late-Session Rebound But Still Finish Lower Wednesday, 18 Jul 2007 | 4:06 PM ET

    Stocks rebounded in late trading but still finished lower as concern about fallout in the subprime industry put a temporary brake on the Dow's run to 14,000. "Subprime isn't good news, but despite this the market will still rally higher," said Jordan Kotick, global head of technical strategy at Barclays Capital.

  • Pfizer Profit Falls Unexpectedly; Lipitor Sales Decline Wednesday, 18 Jul 2007 | 3:43 PM ET

    Pfizer Wednesday reported lower-than-expected quarterly earnings on competition with generics, and said global sales of cholesterol fighter Lipitor fell 13% amid slipping demand for the company's flagship product.

  • Pfizer And Lipitor: Prescription For Big Loss Wednesday, 18 Jul 2007 | 11:19 AM ET
    Exubera

    Yesterday, I blogged that you should watch the Lipitor number in Pfizer's earnings report today. Well, the world's biggest drug company, is having major problems with the world's biggest-selling drug. Lipitor sales fell a surprising 25% in the U.S. and 13% worldwide in the second quarter. And the company says for the full year revenue from the cholesterol fighter could be down as much as 5%.

  • Morning Upgrades and Downgrades: Punk Cuts the Brokers Wednesday, 18 Jul 2007 | 8:59 AM ET

    The revelation that two of Bear Stearns' collateralized debt obligation funds are virtually worthless are casting a pall on the overall market this morning. The biggest factor with the subprime prime epidemic is the great unknown of exposure and containment.

  • 2007 World Series of Poker Final Table

    The Final Table of the World Series of Poker begins today at 3 p.m ET. You can order it on ESPN.com for $19.95 and watch it live if you want. I’m not going to talk about specific names, so there’s no need to turn away if you don’t want to know who made it the finals. Enough of the disclaimers. Now let’s get to the point.

Most Popular Video

Thursday, 24 Apr 2014 | 1:05 AM ET

Jerry Braakman, chief investment officer at First American Trust, says Apple and Facebook reported "great" results and owning technology stocks is still attractive.

Thursday, 24 Apr 2014 | 12:16 AM ET

Manpreet Gill, Senior Investment Strategist at Standard Chartered Bank, attributes the decline of Japanese shares to the lack of a TPP agreement during U.S. President Barack Obama's visit to Tokyo.

Wednesday, 23 Apr 2014 | 3:00 PM ET

CNBC's Becky Quick discusses Warren Buffett's feelings about Coke, IBM and his general sentiment about the market.